Aspirin

Org: University of Besançon, Etablissement Français du Sang Bourgogne Franche-Comté, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Hôpital Henri-Mondor, AP-HP - Université de Paris Est,

Clinical trial

Implementing Screening for Preeclampsia in Norway With Aspirin Discontinuation at 24-28 Weeks - a Randomized Controlled Trial

Status: Recruiting, Estimated PCD: 2025-07-01

Abstract

Association of higher baseline stress and pain with clinical outcomes: Secondary analysis from Alliance A011502.

Org: Channing Laboratory, Johns Hopkins Kimmel Cancer Center, Sweetwater Regional Cancer Center,

Abstract

Correlation of stress, depression, sleep, and pain with race and body mass index (BMI): Secondary analysis from Alliance A011502.

Org: Roswell Park Comprehensive Cancer Center, Mayo Clinic, Channing Laboratory, Johns Hopkins Kimmel Cancer Center, Sweetwater Regional Cancer Center,

Abstract

Efficacy of low-dose direct oral anticoagulants (DOACs) for venous thromboembolism prophylaxis in newly diagnosed multiple myeloma.

Org: Cleveland Clinic Taussig Cancer Instititute,

Clinical trial

ASPIRED-XT: ASPirin Intervention for the REDuction of Colorectal Cancer Risk -EXTension

Status: Recruiting, Estimated PCD: 2024-09-30

Clinical trial

A Randomized, Phase II, Double-blind, Placebo-controlled, Multicenter, 2x2 Factorial Design Biomarker Tertiary Prevention Trial of Low-dose Aspirin and Metformin in Stage I-III Colorectal Cancer Patients. The ASAMET Trial

Status: Active (not recruiting), Estimated PCD: 2024-03-31

Clinical trial

Pembrolizumab in Combination With Anti-platelet Therapy for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Status: Recruiting, Estimated PCD: 2024-06-30

Clinical trial

Anticoagulation Using Rivaroxaban on Top of Aspirin in Recent Stroke/Transient Ischemic Attack Patients With Intracranial Atherosclerotic Stenosis (AA-ICAS)

Status: Not yet recruiting, Estimated PCD: 2024-12-01

Clinical trial

A Study of Cardiovascular Events iN Diabetes - A Randomized 2x2 Factorial Study of Aspirin Versus Placebo, and of Omega-3 Fatty Acid Supplementation Versus Placebo, for Primary Prevention of Cardiovascular Events in People With Diabetes

Status: Active (not recruiting), Estimated PCD: 2018-03-12

Clinical trial

Effects of Postoperative Aspirin on Ankle Fracture Healing

Status: Recruiting, Estimated PCD: 2025-01-01

Clinical trial

The Effect of Low-dose Salicylate Treatment on Platelet Function in Patients With Renal Failure Treated With Darbepoetin Alfa

Status: Recruiting, Estimated PCD: 2026-12-31

Clinical trial

Intensified Tuberculosis Treatment to Reduce the Mortality of HIV-infected and Uninfected Patients With Tuberculosis Meningitis: a Phase III Randomized Controlled Trial (Acronym: INTENSE-TBM)

Status: Recruiting, Estimated PCD: 2025-09-01

Clinical trial

Adjuvant Aspirin Treatment in PIK3CA Mutated Colon Cancer Patients. A Randomized, Double-blinded, Placebo-controlled, Phase III Trial

Status: Active (not recruiting), Estimated PCD: 2023-09-14

Clinical trial

A Phase III Multi-center Randomized Placebo-controlled Study of the Protective Effect of Low-dose Aspirin on Renal Function in Patients With Early Diabetic

Status: Not yet recruiting, Estimated PCD: 2027-01-30

Clinical trial

SMart Angioplasty Research Team: Comparison Between P2Y12 Inhibitor MonotHerapy and Dual Antiplatelet Therapy in Patients UndergOing Implantation of Coronary BiorEsorbable Scaffold II: (SMART-CHOICE II) Trial

Status: Terminated, Estimated PCD: 2017-12-18

Clinical trial

A Randomized Double-blind Placebo-controlled Study With ASA Treatment in Colorectal Cancer Patients With Mutations in the PI3K Signaling Pathway

Status: Active (not recruiting), Estimated PCD: 2024-08-01

Clinical trial

Efficacy of Immunoglobulin Plus Prednisolone in Reducing Coronary Artery Lesion in Patients With Kawasaki Disease: A Multicentre Randomised Controlled Trial

Status: Recruiting, Estimated PCD: 2024-09-01

Clinical trial

A Randomized Controlled Trial Comparing Low Doses Of Aspirin In The Prevention Of Preeclampsia (ASAPP)

Status: , Estimated PCD: 2024-08-01

Clinical trial

ASPIRED: ASPirin Intervention for the REDuction of Colorectal Cancer Risk

Status: Active (not recruiting), Estimated PCD: 2019-04-11

Clinical trial

Program on Genetic and Dietary Predictors of Drug Response in Rural and AI/AN Populations, Project-3, SA-3, Anti-platelet Response

Status: Terminated, Estimated PCD: 2023-07-31

Clinical trial

Safety and Efficacy of Low Dose Colchicine or Prednisone Combining With Standard Drug in Patients With Recurrent In-stent Restenosis: a Prospective, Randomized, Open-label Trial

Status: Not yet recruiting, Estimated PCD: 2024-10-29

Clinical trial

Interventional, Open-label, Repeated Single-dose Trial Investigating the Effects of Enzyme Inhibition on the Pharmacokinetic Profile of Lu AF28996 and Its Metabolites in Healthy Participants

Status: Completed, Estimated PCD: 2024-05-19

Clinical trial

Impact of Perioperative Maintenance or Interruption of Low-dose Aspirin on Recurrence Rate and Thrombotic Events After Burr-hole Drainage of Chronic Subdural Hematoma: a Randomized, Placebo Controlled, Double Blinded Study

Status: Completed, Estimated PCD: 2023-12-31

Clinical trial

Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers - An International, Multi-Center, Double Blind, Randomized Placebo Controlled Phase III Trial

Status: Active (not recruiting), Estimated PCD: 2024-06-01

Clinical trial

Randomized Comparison of Morning Versus Bedtime Administration of Aspirin: A Cardiovascular Circadian Chronotherapy (C3) Trial

Status: Recruiting, Estimated PCD: 2027-01-15

Clinical trial

Optimal Dosing For Low-Dose Aspirin Chemoprophylaxis For Venous Thromboembolism (VTE) Following Total Joint Arthroplasty - A Multi-center Prospective Randomized Control Trial.

Status: Recruiting, Estimated PCD: 2025-03-01

Clinical trial

Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation

Status: Completed, Estimated PCD: 2023-10-27

Clinical trial

Evaluating Intermittent Dosing of Aspirin for Colorectal Cancer Chemoprevention

Status: Active (not recruiting), Estimated PCD: 2023-01-31

Clinical trial

Acetylsalicylic Acid as Secondary Prevention in Colorectal Cancer

Status: Active (not recruiting), Estimated PCD: 2022-02-01

Clinical trial

Anticoagulation in Intracerebral Hemorrhage (ICH) Survivors for Stroke Prevention and Recovery

Status: Recruiting, Estimated PCD: 2027-04-01

Clinical trial

Paclitaxel-Coated Balloon Versus Zotarolimus-Eluting Stent for Treatment of De Novo Coronary Artery Lesions: an Open-label, Multicenter, Randomized, Non-inferiority Trial

Status: Active (not recruiting), Estimated PCD: 2024-02-01

Clinical trial

Aspirin for the Treatment of Vascular Dysfunction After Preeclampsia

Status: Recruiting, Estimated PCD: 2025-11-01

Clinical trial

Patterns of Sleep Restriction and Recovery: The Inflammatory Resolution Pathways

Status: Active (not recruiting), Estimated PCD: 2024-12-01

Clinical trial

MidregiOnal Proatrial Natriuretic Peptide to Guide SEcondary Stroke Prevention: The MOSES-study. An International, Multicentre, Randomised-controlled, Two-arm, Assessor-blinded Trial

Status: Recruiting, Estimated PCD: 2025-01-31

Clinical trial

Aspirin for the Prevention of Preeclampsia and Pregnancy Outcomes in Nulliparous Women After Assisted Reproductive Technology. APPART

Status: Recruiting, Estimated PCD: 2025-05-01

Clinical trial

Anticoagulation Alone Versus Anticoagulation and Aspirin Following Transcatheter Aortic Valve Interventions - an Open, Multicenter Randomized Controlled Trial With Two Parallel Arms (1:1)

Status: Recruiting, Estimated PCD: 2023-02-02

Clinical trial

IndObufen Versus asPirin After Coronary Drug-eluting Stent implantaTION in Elderly Patients With Acute Coronary Syndrome

Status: Not yet recruiting, Estimated PCD: 2026-05-31

Clinical trial

Effect of Aspirin on Biomarkers of Barrett's Esophagus After Successful Eradication of Barrett's Esophagus With Radiofrequency Ablation

Status: Active (not recruiting), Estimated PCD: 2019-06-18

Clinical trial

The Benefit/Risk Profile of Pegylated Proline-Interferon Alpha-2b (AOP2014) Added to the Best Available Strategy Based on Phlebotomies in Low-risk Patients With Polycythemia Vera (PV). The Low-PV Randomized Trial

Status: Completed, Estimated PCD: 2022-03-31

Clinical trial

The Role of Thomboxane A2 and it's Receptor in Vascular Regulation in Women With Endometriosis

Status: Recruiting, Estimated PCD: 2026-08-01

Clinical trial

The Safety of Ticagrelor Monotherapy After Primary Percutaneous Coronary Intervention for ST-elevation Myocardial Infarction and the Effect on Intramyocardial Haemorrhage

Status: Recruiting, Estimated PCD: 2025-07-06

Clinical trial

Phase IIA Clinical Biomarker Trial of Aspirin and Arginine Restriction in Colorectal Cancer Patients

Status: Completed, Estimated PCD: 2013-11-26

Clinical trial

Randomized Controlled Trial to Explore Interaction Between Aspirin and Clopidogrel in Stable Patients With Previous Myocardial Infarction or Coronary Artery Stent

Status: Completed, Estimated PCD: 2013-04-01

Clinical trial

Genetic, Laboratory and Clinical Factors Associated With Low-dose Aspirin Failure in the Prevention of Preeclampsia- An Exploratory Protocol

Status: Recruiting, Estimated PCD: 2025-11-01

Clinical trial

Safety and Efficacy of Ticagrelor Single Antiplatelet Therapy in Patients With High Risk of Bleeding After Drug-coated Balloons for Coronary Small Vessel Disease: A Prospective, Randomized, Open-label, Blinded-endpoint Evaluation, Single-center Study

Status: Not yet recruiting, Estimated PCD: 2024-11-30

Clinical trial

IMPACT: A Phase 0 Randomized Window-of-Opportunity Study of Novel and Repurposed Therapeutic Agents in Women Triaged to Primary Surgery for Advanced Epithelial Ovarian Cancer in Stages IIIa - IV.

Status: Completed, Estimated PCD: 2023-01-05

Clinical trial

An Early Phase 1 Trial of Omeprazole and Low Dose Aspirin to Identify Colorectal Biomarkers of Preventive Efficacy: The Omeprazole and Aspirin Polyp Prevention Study

Status: Recruiting, Estimated PCD: 2025-07-01

Clinical trial

Women With Chest Pain and Normal Coronary Arteries Study: A Randomized Study of Medical Treatment and Therapeutic Lifestyle Changes

Status: Terminated, Estimated PCD: 2010-05-01

Clinical trial

A Randomized Controlled sTudy of Low Dose vs Standard Dose of tIcaGrelor on Platelet Function After intErvention for Acute Coronary syndRome in Diabetes Mellitus Patients

Status: Recruiting, Estimated PCD: 2024-04-30

Clinical trial

Novel Pathways of Eicosanoid Metabolism

Status: , Estimated PCD: 2023-05-31

Clinical trial

Less Bleeding by Omitting Aspirin in Non-ST-segment Elevation Acute Coronary Syndrome Patients

Status: Recruiting, Estimated PCD: 2025-07-01

Clinical trial

Impact of Aspirin Use on the Severity of Organ Dysfunctions in Patients With Sepsis and Septic Shock: a Randomized, Double-blind, Placebo-controlled Trial - ASP-SEPSIS.

Status: Terminated, Estimated PCD: 2022-12-15

Clinical trial

Early Intensive Medical Therapy for the Prevention of Early Neurological Deterioration in Branch Atheromatous Disease

Status: Recruiting, Estimated PCD: 2024-02-28

Clinical trial

Use of 81 vs 325mg of ASA in Treatment of BCVI: A Feasibility RCT

Status: Not yet recruiting, Estimated PCD: 2025-05-01

Clinical trial

Microvascular and Antiinflammatory Effects of Rivaroxaban Compared to Low Dose Aspirin in Type-2 Diabetic Patients With Very High Cardiovascular Risk and Subclinical Inflammation

Status: Completed, Estimated PCD: 2018-12-12

Clinical trial

Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD

Status: Active (not recruiting), Estimated PCD: 2024-09-30

Clinical trial

ASPirin in Immune thRombocytopenia Patients With Cardiovascular disEase

Status: Recruiting, Estimated PCD: 2025-01-01

Clinical trial

Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate Episodes - An Investigator-driven, Prospective, Randomised, Double-blind, Multi-centre Trial Initiated by the European Society of Cardiology and AFNET

Status: Terminated, Estimated PCD: 2022-12-31

Clinical trial

Aspirin Combined With Clopidogrel Versus Intravenous Alteplase for Acute Minor Stroke: An Open-label, Blinded Endpoint, Randomized Controlled Trial

Status: Not yet recruiting, Estimated PCD: 2027-07-01

Clinical trial

A Phase II Study Evaluating Osimertinib Combined With Aspirin Neoadjuvant Therapy for Resectable EGFR Mutated Non-small Cell Lung Cancer (NSCLC)

Status: Not yet recruiting, Estimated PCD: 2026-03-01

Clinical trial

The Optimal Anticoagulation for Enhanced Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial

Status: Active (not recruiting), Estimated PCD: 2025-07-01

Clinical trial

A Randomized Phase II Double-Blind Placebo-Controlled Trial of Acetylsalicylic Acid (ASA) in Prevention of Ovarian Cancer in Women With BRCA 1/2 Mutations (STICs and STONEs)

Status: Active (not recruiting), Estimated PCD: 2024-12-15

Clinical trial

A Proof of Concept Window Trial of the IMmunological Effects of AveLumab and Aspirin in Triple-Negative Breast Cancer

Status: Not yet recruiting, Estimated PCD: 2024-09-30

Clinical trial

The Impact of Aspirin Dose Modification on the Innate Immune Response - Will Lower Dose Aspirin Therapy Reduce the Response to Endotoxin

Status: Completed, Estimated PCD: 2021-12-10

Clinical trial

Aspirin to Target Arterial Events in Chronic Kidney Disease

Status: Recruiting, Estimated PCD: 2025-12-01

Clinical trial

Evaluation of Safety and Efficacy of Two Ticagrelor-based De-escalation Antiplatelet Strategies in Acute Coronary Syndrome: the Randomized, Multicenter, Double-blind ELECTRA RCT Study

Status: Recruiting, Estimated PCD: 2024-06-30

Clinical trial

Enrichment of CES1 Carriers in the Pharmacogenomics Anti-Platelet Intervention Study

Status: Completed, Estimated PCD: 2020-01-17

Clinical trial

Chronotherapy With Low-dose Aspirin for Primary Prevention of Cardiovascular Events in Subjects With Impaired Fasting Glucose or Diabetes (CARING Study).

Status: Recruiting, Estimated PCD: 2025-12-01

Clinical trial

AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke

Status: Terminated, Estimated PCD: 2023-03-31

Clinical trial

Biomarkers and Antithrombotic Treatment in Cervical Artery Dissection - TREAT-CAD

Status: Completed, Estimated PCD: 2019-06-01

Clinical trial

Clopidogrel Versus Aspirin Monotherapy Beyond Twelve Months After Percutaneous Coronary Intervention in Patients at High Risk for Recurrent Ischemic Events

Status: Recruiting, Estimated PCD: 2024-07-31

Clinical trial

Randomised Evaluation of COVID-19 Therapy

Status: Recruiting, Estimated PCD: 2026-06-30

Clinical trial

A Phase II Study of the Anti-PDL1 Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid to Investigate Safety and Efficacy of This Combination in Recurrent Platinum-resistant Ovarian, Fallopian Tube or Primary Peritoneal Adenocarcinoma

Status: Completed, Estimated PCD: 2021-06-01

Clinical trial

CHADSS: Chagas Disease Scan Study

Status: Recruiting, Estimated PCD: 2024-06-01

Clinical trial

A Phase III Trial of Acetylsalicylic Acid and Atorvastatin in Patients With Castrate-resistant Prostate Cancer

Status: Recruiting, Estimated PCD: 2034-03-01

Clinical trial

A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial

Status: Terminated, Estimated PCD: 2021-12-13

Clinical trial

Switching From Standard of Care Dual Antiplatelet Treatment (DAPT) Regimens With Aspirin Plus a P2Y12 Inhibitor to Dual Pathway Inhibition (DPI) With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease: The Switching Anti-Platelet and Anti-Coagulant Therapy (SWAP-AC) Study

Status: Completed, Estimated PCD: 2022-01-31

Clinical trial

DAILY: Vitamin D, Aspirin, ExercIse, Low Saturated Fat Foods StudY in Colorectal Cancer Patients With Minimal Residual Disease

Status: Recruiting, Estimated PCD: 2025-04-30

Clinical trial

Multifactorial Intervention of Primary Prevention in High Risk Subjects: a Randomized Trial

Status: Active (not recruiting), Estimated PCD: 2024-12-31

Clinical trial

A Phase 2 Randomized Discontinuation Trial in Patients With Hormone-Dependent Rising Prostate-Specific Antigen Progression After Local Therapy for Prostate Cancer Evaluating the Synergy of Metformin Plus Aspirin (PRIMA Trial)

Status: Terminated, Estimated PCD: 2019-12-01

Clinical trial

Anticoagulant Plus Antiplatelet Therapy Following Iliac Vein Stenting

Status: Recruiting, Estimated PCD: 2025-12-31

Clinical trial

Randomized Multi-center Clinical Trial to Assess Effectiveness and Safety of Tirofiban Versus Intravenous Aspirin in Patients With Acute Ischemic Stroke Secondary to Tandem Injury, Subject to Recanalization Therapy Through Endovascular Treatment

Status: Recruiting, Estimated PCD: 2025-06-01

Clinical trial

A Phase I Study of Moxetumomab Pasudotox-tdfk (Lumoxiti (TM)) and Either Rituximab (Rituxan (R)) or Ruxience for Relapsed Hairy Cell Leukemia

Status: Active (not recruiting), Estimated PCD: 2023-07-07

Clinical trial

The Clinical Features and Pregnancy Outcomes of Patients With Connective Tissue Disease :a Prospective Cohort Study

Status: Recruiting, Estimated PCD: 2025-06-30

Clinical trial

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

Status: Recruiting, Estimated PCD: 2026-02-01

Clinical trial

A Parallel Group Study in Healthy Participants to Quantitate Increases in Subclinical Gastrointestinal Blood Loss Following Administration of Aspirin Alone or in Combination With Rivaroxaban or Factor XI Inhibitors (REGN9933 or REGN7508)

Status: Not yet recruiting, Estimated PCD: 2025-04-07

Abstract

Effect of astragalus polysaccharides (PG2) treatment of adjuvant chemotherapy-induced fatigue in premenopausal patients with breast cancer.

Org: E-Da Cancer Hospital, Chang Gung Memorial Hospital, Evergreen Health Precision Clinic,

Abstract

BREAKWATER: An open-label, multicenter, randomized, phase 3 study, with a safety lead-in (SLI), of first-line (1L) encorafenib (E) + cetuximab (C) ± chemotherapy (CT) vs standard-of-care (SOC) CT for BRAF V600E-mutant metastatic colorectal cancer (mCRC).

Org: MD Anderson Cancer Center, National Cancer Center Hospital East, Kashiwa, Japan, Asan Medical Center, Hammersmith Hospital, Imperial College, London, United Kingdom, Department of Gastroenterology/Digestive Oncology,

Abstract

Temsirolimus (T) in patients (pts) with solid tumors with PIK3CA mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.

Org: Sylvester Comprehensive Cancer Center, Miami, FL, University of Miami Miller School of Medicine, Miami, FL, American Society of Clinical Oncology, Herbert-Herman Cancer Center, Michigan Cancer Research Consortium,

Abstract

Preliminary results from ERAS-007 plus encorafenib and cetuximab (EC) in patients (pts) with metastatic BRAF V600E mutated colorectal cancer (CRC) in HERKULES-3 study: A phase 1b/2 study of agents targeting the mitogen-activated protein kinase (MAPK) pathway in pts with advanced gastrointestinal malignancies (GI cancers).

Org: University of Texas MD Anderson Cancer Center, Department of Medicine, Icahn School of Medicine at Mount Sinai, Division of Hematology & Oncology, Massachusetts General Hospital, Harvard Medical School,

Abstract

Evaluation of ICI sensitivity for pembrolizumab in combination with anti-platelet therapy for patients with recurrent or metastatic squamous cell carcinoma of the head and neck (HNSCC).

Org: The Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center and Pelotonia Institute for Immuno-Oncology, Columbus, OH, Columbus, OH, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC,

Abstract

Safety and efficacy of QL1706 plus carboplatin/etoposide (EC) as first-line (1L) treatment for extensive-stage small-cell lung cancer (ES-SCLC): The results from a phase II single-arm study.

Org: Zhejiang Cancer Hospital, Chinese Academy of Sciences, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Yunnan Cancer Hospital, Kunming, Yunnan, China, Anhui Chest Hospital,

Abstract

Epidemiologic effectors on the breast tumor microenvironment: Results from the Cancer Prevention Study-II and -3 cohorts.

Org: John H. Stroger, Jr. Hospital of Cook County, Northwestern University Feinberg School of Medicine, American Cancer Society, National Cancer Institute, Vilnius, Lithuania, Robert H. Lurie Comprehensive Cancer Center, Northwestern University,

Abstract

Associating patient perceptions to poor uptake of aspirin (ASA) chemoprevention in a single-center cohort of patients with Lynch syndrome (LS).

Org: Crozer-Chester Medical Center, Fox Chase Cancer Center,

Abstract

Augmented curation of disease diagnoses and medications for patients with hepatocellular carcinoma.

Org: nference, nference Labs,

Abstract

Effect on in-hospital outcomes of patients with hepatocellular carcinoma on aspirin.

Org: University of Arizona, Liver Institute Northwest, University of California San Francisco- Fresno, Dayanand Medical College & Hospital, Punjab Institute of Medical Sciences,

Abstract

Estimating burden of cardiovascular disease among survivors of breast, colorectal, lung, and prostate cancer in the Detroit Research on Cancer Survivors (ROCS) cohort.

Org: Ascension Providence Hospital/Michigan State University, Barbara Ann Karmanos Cancer Institute, Wayne State University, MedStar Health Research Institute, University of Pittsburgh Medical Center,

Abstract

External validation of venous thromboembolism risk prediction models in patients with multiple myeloma in a community setting: A retrospective cohort study.

Org: Saint Vincent Hospital Cancer Center Green Bay, University of Pittsburgh Medical Center Cancer Center, Saint Vincent Cancer and Wellness Center, Saint Vincent Hospital, Department of Hematology/Oncology, Internal Medicine, St. Vincent Hospital,

Abstract

Two-year lung cancer survival between 2000 to 2020: Results from 3 French nationwide cohorts.

Org: Service de Pneumologie, Groupe Hospitalier de la Région Mulhouse Sud-Alsace, hôpital Émile-Muller, Mulhouse, France, CHI De Creteil, Créteil, France, HIA SAINTE ANNE, Toulon, France, Hospital Center De La Cote Basque, Bayonne, France, Centre Hospitalier, Le Mans, France,

Abstract

Non-vitamin k oral antagonists versus aspirin for primary thromboprophylaxis in patients with multiple myeloma on outpatient chemotherapy: A systematic review and meta-analysis.

Org: Federal University of Ceará, Fortaleza, Brazil, Mount Sinai Morningside and West, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, Federal University of Campina Grande, Cardiff University School of Medicine,

Abstract

Cardiovascular comorbidities and cardiovascular events in patients with metastatic prostate cancer.

Org: Laboratoire Toxicomed, University of Tlemcen, Tidjani Damerdji Teaching Hospital, CHU Tlemcen,

Abstract

Effect of durable hematocrit control and minimal thrombotic risk in real-world polycythemia vera patients treated with ruxolitinib.

Org: Levine Cancer Institute Atrium Health, Levine Cancer Institute, Department of Hematologic Malignancies and Blood Disorders, Yale School of Medicine, Yale University,

Product

Aggrenox

Product

BC3195

Product

AA+P

Clinical trial

Safety and Efficacy of Ticagrelor With Low-dose Aspirin Versus Regular Aspirin in Patients With Acute Coronary Syndrome at High-risk for Ischemia After Percutaneous Coronary Intervention: A Randomized Controlled Study

Status: Recruiting, Estimated PCD: 2025-12-01

Clinical trial

A Prospective Observational Cohort Study of Predictive Factors Related to Prognosis of In-hosiptal Patients With Ischemic Stroke Due to Large-artery Atherosclerosis

Status: Recruiting, Estimated PCD: 2026-12-31

Clinical trial

Thrombopoietin Receptor Agonist (TPO-RA) Treatment on Immune Tolerance Induction of ITP Patients With Sustained Platelet Recovery After Treatment Termination

Status: Recruiting, Estimated PCD: 2027-06-20

Clinical trial

Stroke Prevention In Ischemic Stroke With Covert Atrial Fibrillation

Status: Not yet recruiting, Estimated PCD: 2025-09-01